Adverse Effects Of Blood Transfusion Practice Test

Hemovigilance is the systematic surveillance of transfusion-related adverse events, spanning from the donor through the transfusion to the patient. In the United States, hospitals work with the American Association of Blood Banks (AABB) and the Centers for Disease Control and Prevention (CDC) in a cooperative Hemovigilance program to report every transfusion adverse event. This program collects data on reactions (like fever, chills, anaphylaxis, TRALI, TACO), transfusion-transmitted infections, labeling or handling errors, and near-miss events, then analyzes the information to identify patterns and root causes. The goal is to prompt corrective actions—education, process changes, and policy updates—to prevent recurrence and improve overall transfusion safety. The other names don’t reflect this formal, national surveillance framework.